The latest price target for X4 Pharmaceuticals (NASDAQ:XFOR) was reported by HC Wainwright & Co. on January 14, 2025. The analyst firm set a price target for $1.50 expecting XFOR to rise to within 12 months (a possible 212.37% upside). 7 analyst firms have reported ratings in the last year.

The latest analyst rating for X4 Pharmaceuticals (NASDAQ:XFOR) was provided by HC Wainwright & Co., and X4 Pharmaceuticals reiterated their buy rating.

There is no last upgrade for X4 Pharmaceuticals

The last downgrade for X4 Pharmaceuticals Inc happened on December 12, 2023 when B. Riley Securities changed their price target from $3 to $1 for X4 Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of X4 Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for X4 Pharmaceuticals was filed on January 14, 2025 so you should expect the next rating to be made available sometime around January 14, 2026.

While ratings are subjective and will change, the latest X4 Pharmaceuticals (XFOR) rating was a reiterated with a price target of $1.50 to $1.50. The current price X4 Pharmaceuticals (XFOR) is trading at is $0.48, which is out of the analyst’s predicted range.